Navigation Links
Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
Date:2/13/2008

Review of VistaCare's first quarter operating results further convinces

Accipiter that Odyssey is acquiring VistaCare at a discount

NEW YORK, Feb. 13 /PRNewswire/ -- Accipiter Capital Management, the owner, together with its affiliates, of nearly 10% of the outstanding shares of common stock of VistaCare, Inc. (Nasdaq: VSTA), announced today that it had delivered a letter to VistaCare's Board of Directors stating that a review of VistaCare's Quarterly Report for the quarterly period ended December 31, 2007, has further convinced Accipiter that the offer by Odyssey Healthcare, Inc. (Nasdaq: ODSY) to acquire VistaCare for $8.60 per share is wholly inadequate. The letter further indicated that Accipiter was troubled by inconsistencies between VistaCare's internal analysis of the Company's restructuring and information VistaCare's management disclosed to investors. The letter calls on VistaCare's Board of Directors to explain these inconsistencies to stockholders and urges stockholders not to tender their shares in connection with the acquisition and to exercise their appraisal rights to the full extent permissible under law should the tender offer and subsequent merger be consummated.

Accipiter Capital Management and its affiliates do not intend to tender their shares in connection with the acquisition and plan to exercise their appraisal rights to the full extent permissible under law should the tender offer and subsequent merger be consummated. The text of the letter from Accipiter Capital Management to the Board of Directors of VistaCare follows:

ACCIPITER CAPITAL MANAGEMENT

February 13, 2008

BY FACSIMILE AND FEDERAL EXPRESS

The Board of Directors

VistaCare, Inc.

4800 North Scottsdale Road

Suite 5000

Scottsdale, AZ 85251

Ladies and Gentlemen:

Accipiter Capital Management and its affiliates (collectively "Accipiter" or "we") have reviewed the Quarterly Report for the quarterly period ended December 31, 2007 (the "10-Q"), filed by VistaCare, Inc. ("VistaCare" or the "Company") on February 8, 2008. Careful review of VistaCare's results for its first fiscal quarter (the "First Quarter") as disclosed in the 10-Q has reinforced our belief that the offer by Odyssey Healthcare, Inc., through Odyssey Investment, Inc., a wholly owned subsidiary of Odyssey HealthCare Holding Company (collectively, "Odyssey") to acquire the Company for $8.60 per share (the "Acquisition") is a discount bid rather than a premium.

It is clear to us from the 10-Q that VistaCare significantly outperformed analyst expectations for the First Quarter -- reporting EBITDA of $2.2 million and earnings per share of $0.09 versus analysts' estimates of $1.6 million of EBITDA and earnings per share of $0.05. If VistaCare were to remain independent, we believe the Company's future results would be even higher considering VistaCare's corporate restructuring activities (the "Restructuring") occurred throughout the quarter and the full benefits are not yet fully reflected Company's operating results. Although VistaCare publicly disclosed in its Solicitation/Recommendation Statement filed on January 30, 2008 (the "Recommendation") that the Restructuring has fallen behind internal expectations, independent analyst estimates signal, and the results disclosed in the 10-Q confirm, that the Restructuring is well ahead of Wall Street's expectations. Furthermore, the 10-Q signifies strong cash flow, as indicated by the increase in the cash net of VistaCare's Medicare cap liability from $18 million on September 30, 2007 to $23 million on December 31, 2007. Based on these results we believe VistaCare is effectively being purchased for $7.20 per share in enterprise value, $0.30 lower than our previous estimate. In fact, these results have further convinced us that had VistaCare not agreed to a takeover, the Company's stock price would currently be well ahead of the $8.60 per share purchase price being offered by Odyssey.

Although we are pleased with VistaCare's restructuring success so far, we are also troubled by the Company's disclosure in the 10-Q relating to inconsistencies between management's internal analysis of the Restructuring's progress versus the information the Company's management disclosed to investors. For example, as first publicly disclosed in the Recommendation, on November 14, 2007, management noted to the Board that the estimated benefits of the Restructuring would not be realized as soon as initially projected and, therefore, fiscal 2008 projected financial targets may be lower than forecasted. However, management made no mention of this on their quarterly conference call, held on December 11, 2007. In fact, on that particular call Rick Slager, VistaCare's Chief Executive Officer, spoke positively about the Company's turnaround progress, stating, "[w]e made substantial progress towards achieving the goals of our restructuring plan during this fiscal fourth quarter." Additionally, when Henry Hirvela, VistaCare's Chief Financial Officer, was asked about the Company's goal of 10% EBITDA for the fourth quarter of fiscal 2008, he responded, "I think that is pretty much the guidance that we are going to be staying with as we go forward." We call on the Board to explain these inconsistencies to investors.

We are also troubled by other recent actions taken by management. In particular,

-- We note that VistaCare waited to disclose that the Company was behind

on the Restructuring until January 30, 2008, more than two months

after disclosing this to the Board.

-- We note that VistaCare failed to hold a conference call to discuss

the Acquisition or to discuss the December Quarter results.

-- We note that if the merger is consummated and management is not

retained, VistaCare's CEO will receive severance payments of

approximately $1.73 million, three times his then current salary,

plus benefits for three years, upon termination after a change of

control, in spite of the fact that, up to this point, the Company's

profitability severely lags relative to its peers.

As this is a strategic acquisition, we anticipate Odyssey will seek to achieve cost savings by reducing redundant management. So who stands to gain the most if Odyssey acquires VistaCare -- VistaCare's stockholders or its management who will be handsomely rewarded if terminated?

We believe that VistaCare would be significantly more valuable as a standalone company with new management more capable of effectuating a timely turnaround. Consequently, we strongly urge stockholders not to tender their shares to Odyssey and to exercise their appraisal rights in accordance with Section 262 of the Delaware General Corporation Law should the tender offer and subsequent merger be consummated.

Sincerely,

Gabe Hoffman Nicole Viglucci


'/>"/>
SOURCE Accipiter Capital Management
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rural/Metro Board of Directors Meets With Accipiter Capital Management
2. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. AtriCure to Present at Roth Capital Partners 2007 New York Conference
5. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
6. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
7. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
8. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
9. Pharsight Files Application for Nasdaq Capital Market Listing
10. Advanced Life Sciences Joins NASDAQ Capital Market
11. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: